A
Arduino A. Mangoni
Researcher at Flinders Medical Centre
Publications - 397
Citations - 10350
Arduino A. Mangoni is an academic researcher from Flinders Medical Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 42, co-authored 348 publications receiving 7835 citations. Previous affiliations of Arduino A. Mangoni include University of Cambridge & King's College London.
Papers
More filters
Journal ArticleDOI
Markers of oxidative stress, skeletal muscle mass and function, and their responses to resistance exercise training in older adults.
Ciriaco Carru,Mariasole Da Boit,Panagiotis Paliogiannis,Angelo Zinellu,Salvatore Sotgia,Rachael Sibson,Judith R. Meakin,Richard M. Aspden,Arduino A. Mangoni,Stuart R. Gray +9 more
TL;DR: Plasma MDA, HCY, and TAU were significantly associated with baseline and/or exercise‐induced changes in muscle mass and function in healthy older adults, primarily in females.
Journal ArticleDOI
Enteral tube feeding and mortality in hospitalized older patients: A multicenter longitudinal study
Nicola Veronese,Alberto Cella,Alfonso J. Cruz-Jentoft,Maria Cristina Polidori,Francesco U.S. Mattace-Raso,Marc Paccalin,Eva Topinkova,Antonio Greco,Arduino A. Mangoni,Julia Daragjati,Giacomo Siri,Alberto Pilotto,Clarissa Musacchio,Romina Custureri,Matteo Puntoni,Matteo Simonato,Mario Durando,Carmen Miret-Corchado,Beatriz Montero-Errasquín,Anna Maria Meyer,Dirk Hoffmann,Ralf-Joachim Schulz,Lisanne Tap,Angelique Egberts,Marie-Laure Bureau,Thomas Brunet,Evelyne Liuu,Helena Michalkova,Pavla Madlova,Daniele Sancarlo,Grazia D'Onofrio,Kimberley Ruxton,Stefania Maggi,Luigi Ferrucci +33 more
TL;DR: Investigating whether the Multidimensional Prognostic Index (MPI), an established tool that assesses measures of frailty and predicts mortality, may help physicians in identifying patients in whom ETF (enteral tube feeding) is effective in terms of reduced mortality found it to be associated with a higher risk of death.
Journal ArticleDOI
Homocysteine and cardiovascular risk an old foe creeps back.
TL;DR: Several scoring systems, based on traditional risk factors, are available for the 10-year quantification of cardiovascular (CV) risk for either coronary heart disease (CHD) or cardiovascular disease (CVD) events.
Journal ArticleDOI
Randomized controlled trial of perhexiline on regression of left ventricular hypertrophy in patients with symptomatic hypertrophic cardiomyopathy (RESOLVE-HCM trial)
Rajiv Ananthakrishna,Sau L Lee,Jonathon Foote,Benedetta C. Sallustio,Giulia Binda,Arduino A. Mangoni,Richard J. Woodman,Christopher Semsarian,John D. Horowitz,Joseph B. Selvanayagam,Joseph B. Selvanayagam +10 more
TL;DR: The RESOLVE-HCM trial as discussed by the authors evaluated the effects of perhexiline treatment on the extent of left ventricular hypertrophy (LVH) in symptomatic hypertrophic cardiomyopathy patients with at least moderate LVH.
Journal ArticleDOI
Heat Waves, Drugs with Anticholinergic Effects, and Outcomes in Older Hospitalized Adults
TL;DR: To determine whether heat waves affect exposure to drugs with anticholinergic effects (DACEs) on admission and the effect of such on length of stay (LOS) and in‐hospital mortality in older adults, a large number of older adults are surveyed.